‘A Future of MQL and Managing Risk Release’ Webinar
12 September 2024 | 10am EDT (7am PDT / 3pm BST / 4pm CEST)
This upcoming webinar presented by John R. Logar (Senior Director, Sterility Assurance, Johnson & Johnson) and Sebastian Scheler (Co-Founder, Managing Director, Chief Methodologist, Frame-by-Frame Risk Profiling Supervisor at Innerspace) will provide insight into the concept of Microbiological Quality Level (MQL) and its application in pharmaceutical manufacturing. Find the full abstract below.
The concept of a Microbiological Quality Level (MQL) has been proposed as a method for determining the acceptable level of microbial contamination permitted during the manufacturing of or on a finished pharmaceutical, biopharmaceutical or combination product. The Kilmer RMM and PAT collaboration teams, along with ASTM Committee E55, have been exploring the use of Microbiology Quality Level (MQL) as means to enabling this future and this webinar will introduce and explore this concept as a means of determining probability/quantification of microbial risk for each step and its contribution to the final product as a mechanism to differentiate the microbiological quality of finished product.
Registration is now open and can be found at this link.